POPS RICHARD F

SEC source: 0001126490-26-000005 · wk-form4_1780092309.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,567

Underlying: Common Stock · 2,567 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: The RSUs will vest in full on May 27, 2027.

F2 · derivative.expiration_date: The RSUs will vest in full on May 27, 2027.

SEC source: 0001126490-26-000003 · wk-form4_1779405806.xml · derivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,318 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

SEC source: 0001126490-26-000003 · wk-form4_1779405806.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-26-000027 · wk-form4_1779141036.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2026-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options will expire ten years from the date of grant on May 20, 2026.

SEC source: 0000914475-26-000027 · wk-form4_1779141036.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,480

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on February 13, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.51 to $158.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-26-000027 · wk-form4_1779141036.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001520262-26-000062 · form4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,843

Underlying: Ordinary Shares · 88,843 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 12/31/2026 in connection with the Company's previously announced leadership transition.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 12/31/2026 in connection with the Company's previously announced leadership transition.

SEC source: 0001520262-26-000019 · form4.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,377,740

SEC source: 0001520262-26-000019 · form4.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,439,970

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs.

SEC source: 0000914475-25-000129 · wk-form4_1747949013.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,869 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested.

F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested.

SEC source: 0000914475-25-000129 · wk-form4_1747949013.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000129 · wk-form4_1747949013.xml · derivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,318

Underlying: Common Stock · 3,318 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: The RSUs will vest in full on May 21, 2026.

F2 · derivative.expiration_date: The RSUs will vest in full on May 21, 2026.

SEC source: 0001127602-25-006030 · form4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 293,921

Underlying: Ordinary Shares · 293,921 shares

Expires 2035-02-19

F1 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/19/2026.

SEC source: 0001127602-25-003685 · form4.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,290,390

SEC source: 0001127602-25-003685 · form4.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,370,315

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

SEC source: 0000914475-24-000150 · wk-form4_1716503150.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,869

Underlying: Common Stock · 2,869 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: The RSUs will vest in full on May 22, 2025.

F2 · derivative.expiration_date: The RSUs will vest in full on May 22, 2025.

SEC source: 0000914475-24-000136 · wk-form4_1716326835.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,199 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested.

F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested.

SEC source: 0000914475-24-000136 · wk-form4_1716326835.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,611

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.80 to $142.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

SEC source: 0000914475-24-000136 · wk-form4_1716326835.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000092 · wk-form4_1710537566.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,200 shares

Expires 2025-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.

SEC source: 0000914475-24-000092 · wk-form4_1710537566.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,512

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-24-000092 · wk-form4_1710537566.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,712

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000088 · wk-form4_1710283649.xml · derivative · entry 6

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,200

Underlying: Common Stock · 100 shares

Expires 2025-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.

SEC source: 0000914475-24-000088 · wk-form4_1710283649.xml · nonDerivative · entry 4

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,512

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0000914475-24-000088 · wk-form4_1710283649.xml · nonDerivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,612

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000088 · wk-form4_1710283649.xml · derivative · entry 5

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,300

Underlying: Common Stock · 1,700 shares

Expires 2025-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.

SEC source: 0000914475-24-000088 · wk-form4_1710283649.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,512

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-24-000088 · wk-form4_1710283649.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,212

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 12

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,328

Underlying: Ordinary Shares · 274,328 shares

Expires 2034-02-26

F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/26/2025.

SEC source: 0000914475-24-000078 · wk-form4_1708639891.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2024-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted May 22, 2014 and vested in 12 equal monthly installments beginning June 22, 2014. These options will expire ten years from the date of grant on May 22, 2024.

SEC source: 0000914475-24-000078 · wk-form4_1708639891.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,512

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.64 to $134.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-24-000078 · wk-form4_1708639891.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-004634 · form4.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,179,675

SEC source: 0001127602-24-004634 · form4.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,271,432

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 11

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,570

Underlying: Ordinary Shares · 5,697 shares

Expires 2033-02-23

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 10

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,024

Underlying: Ordinary Shares · 5,980 shares

Expires 2032-02-18

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 9

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 349,030

Underlying: Ordinary Shares · 6,843 shares

Expires 2031-02-22

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 8

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,634

Underlying: Ordinary Shares · 7,168 shares

Expires 2030-02-20

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 7

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 389,844

Underlying: Ordinary Shares · 7,644 shares

Expires 2029-02-21

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares underlying the stock option award shall not vest and become exercisable unless and until the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, is fifty U.S. Dollars (US$50.00) or higher for thirty (30) consecutive trading days during the term of the award (the "performance criteria"). Subject to achievement of the performance criteria, the shares underlying the stock option award shall vest in four equal annual installments commencing on 2/21/2020. This award expires ten years from the date of grant.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 6

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,419

Underlying: Ordinary Shares · 2,419 shares

Expires 2029-02-21

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 5

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,899

Underlying: Ordinary Shares · 5,899 shares

Expires 2028-02-16

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 4

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,999

Underlying: Ordinary Shares · 3,999 shares

Expires 2027-02-17

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,999

Underlying: Ordinary Shares · 5,999 shares

Expires 2026-02-28

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,999

Underlying: Ordinary Shares · 3,999 shares

Expires 2025-02-26

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,599

Underlying: Ordinary Shares · 4,599 shares

Expires 2024-03-03

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001209191-23-031115 · doc4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,199

Underlying: Common Stock · 4,199 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units will vest in full on May 17, 2024.

F2 · derivative.expiration_date: The Restricted Stock Units will vest in full on May 17, 2024.

SEC source: 0001127602-23-007184 · form4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,873

Underlying: Ordinary Shares · 284,873 shares

Expires 2033-02-23

F1 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-23-006518 · form4.xml · derivative · entry 5

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 32,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F3 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-23-006518 · form4.xml · nonDerivative · entry 4

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,052,881

SEC source: 0001127602-23-006518 · form4.xml · nonDerivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,067,267

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.